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The Percutaneous transluminal Angioplasty and Drug eluting stents for Infrapopliteal lesions in critical limb ischemia
(PADI) trial is a prospective, multicenter, randomized, controlled, double-arm study investigating the safety and efficacy
of primary paclitaxel-eluting stent implantation vs primary percutaneous transluminal angioplasty (PTA) in infrapopli-
teal lesions in critical limb ischemia (CLI). PTA with provisional “bailout” stent implantation is currently an accepted
treatment for arterial obstructions in CLI, including those in below-the-knee arteries. A drawback compared to open
bypass surgery is the relatively high restenosis rate. One proposed method to reduce restenosis is the use of drug-eluting
stents (DES), as these have shown good results in the coronary bed. Primary DES implantation for focal obstructions
in infrapopliteal arteries in CLI potentially reduces restenosis compared to PTA alone and may subsequently prolong
effect of treatment, allowing for better wound healing, and preventing recurrence of symptoms. In this article, we report
on rationale, design, and progress of the PADI trial, which investigates the safety and efficacy of a paclitaxel-eluting stent
system compared to PTAwith provisional baremetal stent implantation (Clinicaltrials.gov numberNCT00471289). (J Vasc
Surg 2009;50:687-90.)In patients with critical limb ischemia (CLI) restoration of
pulsatile blood flow to the distal limb is imperative for relief of
symptoms and prevention of (further) tissue loss. Revascular-
ization can be achieved by open surgical bypass or endovascu-
lar techniques, percutaneous transluminal angioplasty (PTA)
with bailout stent implantation being the most widely used
technique.1 Possible advantages of endovascular approach are
lower periprocedural morbidity andmortality, and lower cost.
Short-term data from the bypass versus angioplasty in severe
ischemia of the leg (BASIL) trial has confirmed this, with
similar clinical outcome for surgical and endovascular ap-
proach.2 Long-term results are not yet available. The main
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doi:10.1016/j.jvs.2009.04.073disadvantage of PTA is the relatively high rate of restenosis,
reported to be around 50% after 1 year.3-6
Severe comorbidities and advanced age, typical of this
population, pose increased surgical risk. By reducing reste-
nosis rates, endovascular revascularization can become a
better alternative to bypass surgery.
One proposed method is the use of drug-eluting stents
(DES), which have proven their worth in treatment of
coronary artery disease (CAD). Because of similar vessel
diameter, several investigators have used coronary DES in
infrapopliteal arteries. These studies show very promising
results, but all have considerable limitations due to study
design and small numbers of patients.7-11
The Percutaneous transluminal Angioplasty and Drug
eluting stents for Infrapopliteal lesions in critical limb ischemia
(PADI) trial is designed to further investigate the safety and
efficacy of primary implantation of DES vs standard endovas-
cular therapy (PTA and bailout stent implantation), using a
paclitaxel-eluting stainless steel coronary stent system(TAXUS
Liberté;BostonScientific,Natick,Mass).This systemwaschosen
because of its availability in participating centers.
Trial design. The PADI trial is a multicenter, prospec-
tive, randomized, controlled, nonblinded, double-arm
study conducted in major vascular centers in The Nether-
lands. Eligible subjects are adults with CLI of the lower
limb, defined as Rutherford categories 4 to 6, with obstruc-
tion or occlusion below the level of the knee joint (ie,
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peroneal arteries) and who are considered for endovascular
revascularization.
Inflow proximal to target lesion(s) should be uninter-
rupted, possibly after treatment during the same session.
Outflow distal to target lesion(s) should be unimpeded at
least until the level of the ankle joint. Because of available
stent sizes, reference vessel diameter for target lesions is 2-6
mm andmaximum lesion length is 90mmwith a maximum
of three stents overlapping. Screening of these criteria is by
pretreatment imaging, ie, duplex ultrasound (DUS) scan,
digital subtraction angiography (DSA), magnetic reso-
nance angiography (MRA), or computed tomography an-
giography (CTA). Further inclusion criteria and exclusion
criteria are detailed in Table I. Patients unwilling to partic-
ipate or not meeting all criteria receive standard PTA
treatment. In participating patients, clinical data is recorded
(Rutherford class, ulcer size, extent of gangrene, medical
history/comorbidities, cardiovascular risk factors, and con-
comitant medication); along with ankle-brachial index
Table I. Inclusion and exclusion criteria
Inclusion criteria:
● Age 18 years.
● If female patient with child-bearing potential, patient may not b
the duration of her participation in the study.
● Patient is willing and able to comply with the specified follow
● Critical limb ischemia, this is Fontaine stage III (ischemic res
(ischemic rest pain), 5 (minor tissue loss), or 6 (major tissue
● Stenosis (50% luminal loss) or occlusion of infrapopliteal ar
posterior tibial artery, and the peroneal artery.
● Target lesion length 90 mm.
● Artery to be treated with a diameter 2 mm and 6 mm.
● Patent common iliac, external iliac, superficial femoral and po
after treatment during the same session.
● At least 1 patent crural (anterior tibial, posterior tibial, or per
treatment.
Exclusion criteria:
● Acute limb ischemia.
● Previous amputation of affected limb at or above ankle level.
● Subacute limb ischemia which requires thrombolysis as first t
● Active bleeding or bleeding diathesis.
● Recent (3 months) hemorrhagic stroke or any other CNS a
neoplasm, arteriovenous malformation, intracranial aneurysm
● Gastrointestinal or genitourinary bleeding of clinical significa
● Aneurysm in common femoral, superficial femoral, or poplite
● Surgical revascularization involving the same limb within 30
of the same limb within 30 days of the index procedure.
● Previous implanted stent at the index site.
● Life expectancy of less than 6 months or other factors making
● Known allergy to acetylsalicylic acid (aspirin), clopidogrel, he
● Known allergy to contrast media.
● Known heparin-induced thrombocytopenia (HIT type 2).
● Patient unable or unwilling to tolerate anticoagulant, anti-pla
● Creatinine clearance 20 mL/minute (as derived from Cock
● Severely calcified lesions with expected resistance to stenting.
● Poor inflow due to ipsilateral stenoses or occlusions of the ili
session.
● Significant vessel tortuosity or other parameters prohibiting a
● Patients without (expected) distal runoff to the index site.
● Previous implanted stent at the index site.
CNS, Central nervous system.(ABI) and toe pressure (TP), if available. All patients inboth arms are informed about the risks and (potential)
benefits of DES stenting, the investigational nature of this
procedure prior to the procedure itself, and informed con-
sent is mandatory for randomization. Lesion criteria are
re-evaluated with DSA during treatment. After the target
lesions are passed with a guidewire, subjects are random-
ized on a 1:1 basis to receive either primary paclitaxel-
eluting stent implantation or PTA with optional bailout
stenting using bare metal stents (BMS). Randomization is
per limb and is stratified by center in blocks, the size of
which is known only to the statistician to prevent investi-
gator bias. If both limbs are treated, each limb is random-
ized separately. Subjects in both arms receive 100 mg of
carbasalate calcium daily indefinitely and 75 mg of clopi-
dogrel daily for at least 6 months.
Follow-up consists of clinical evaluation, ABI, TP if
available, and DUS of treated vessel(s) 3, 6, and 12 months
post-treatment. After 6 months, a CTA of the treated limb
is performed. CTA is far less invasive and less burdening to
nant at the study entry and must utilize reliable birth control for
valuation.
) and IV (ischemic ulcers or gangrene) or Rutherford category 4
including the tibiofibular trunk, the anterior tibial artery, the
al artery on the ipsilateral side prior to randomization, possibly
l) artery with expected unobstructed runoff to ankle level after
ent modality.
mality with increased risk of hemorrhage, such as intracranial
neurysm repair.
ithin the previous 6 weeks before treatment.
ery on the ipsilateral side.
rior to the index procedure or planned surgical revascularization
ical follow-up difficult.
, or paclitaxel.
therapy or contrast media.
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tool for assessment of arterial obstructions.12
Primary endpoint of the study is primary binary in
segment patency, defined as less than 50% loss of luminal
diameter on CTA without re-intervention in the interim.
All endpoints are listed in Table II. More preferable clinical
endpoints or long-term patency would require very large
patient populations of more than 300, statistical sample size
calculation showed. Statistical analysis is based on the null
hypothesis that primary patency rates after 6 months are
equal for both study-arms, with an expected patency rate of
50%, based on available literature. Rejection of the null
hypothesis signifies either superior or inferior primary pa-
tency for DES. The primary endpoint will be tested by 2
test, the secondary endpoints by 2 test, combined logistic
regression analysis, Kaplan-Meier curves, and log-rank test.
Sample size was calculated to 136 patients in total, 68 for
each arm.
The PADI trial has been approved by the medical
ethical board of each of the participating centers. It is an
investigator-initiated trial, receiving a grant from The
Netherlands Society for Interventional Radiology.
Study progress. Currently, four major vascular cen-
ters in The Netherlands are recruiting patients. We expect
two more to receive approval from the ethical board and to
start recruiting within a few weeks. Due to discussion
between local medical ethics boards and the Central Com-
mittee involving Human Subjects (Dutch: CCMO) on
whether research involving DES should follow guidelines
on medical device research or clinical drug research, rollout
to centers other than the principle site (Haga Teaching
Hospital) was delayed by almost 2 years (initial approval
Table II. Endpoints
Primary
● Primary patency (defined as 50% loss of luminal diameter
at the treated site on CTA without re-intervention in the
interim) of the treated infra-popliteal artery at 6 months.
Secondary
● Primary patency on duplex sonography scan of the treated
sites at 3 months.
● Primary patency on duplex sonography scan of the treated
sites at 6 months.
● Primary patency on duplex sonography scan of the treated
sites at 12 months.
● Clinical categorization of the treated ischemic leg by means
of the Rutherford classification at 3, 6, and 12 months.
● Major amputation (at or above the ankle) of the trial leg at
3, 6, and 12 months.
● Minor amputation (below the ankle excluding the toes) of
the trial leg at 3, 6, and 12 months.
● Infrapopliteal surgical bypass of the trial leg at 3, 6, and 12
months.
● Infrapopliteal endovascular re-intervention of the trial leg at
3, 6, and 12 months.
● Patency of treated femoropopliteal sites, if applicable.
● Peri-procedural (within 30 days) complications.
● Death.
CTA, Computed tomography angiography.April 2007, final approval December 2008).A total of 19 patients have been included in 15months,
but centers other than the principal site have only just
started recruiting. The relatively strict angiographic criteria
prohibit inclusion of most screened subjects, since many of
them have diffuse arterial disease over long segments.
CONCLUSION
Reducing restenosis rates for endovascular revascular-
ization can make it a better alternative to bypass surgery.
DES have this potential. The PADI trial studies the safety
and efficacy of primary paclitaxel-eluting stent implantation
for infrapopliteal lesions in CLI compared to standard PTA
with optional bailout bare metal stent implantation.
REFERENCES
1. Norgren L, Hiatt WR, Dormandy JA, Nehler MR, Harris KA, Fowkes
FG; TASC II Working Group. Inter-Society Consensus for the Man-
agement of Peripheral Arterial Disease (TASC II). J Vasc Surg 2007;
45(Suppl S):S5-67.
2. AdamDJ, Beard JD, Cleveland T, Bell J, Bradbury AW, Forbes JF, et al.
Bypass versus angioplasty in severe ischaemia of the leg (BASIL):
multicentre, randomised controlled trial. Lancet 2005;366:1925-34.
3. Rand T, Basile A, CejnaM, FleischmannD, FunovicsM, Gschwendtner
M, et al. PTA versus carbofilm-coated stents in infrapopliteal arteries:
pilot study. Cardiovasc Intervent Radiol 2006;29:29-38.
4. Bosiers M, Hart JP, Deloose K, Verbist J, Peeters P. Endovascular
therapy as the primary approach for limb salvage in patients with critical
limb ischemia: experience with 443 infrapopliteal procedures. Vascular
2006;14:63-9.
5. Gargiulo M, Maioli F, Ceccacci T, Morselli-Labate AM, Faggioli G,
Freyrie A, et al. What’s next after optimal infrapopliteal angioplasty?
Clinical and ultrasonographic results of a prospective single-center
study. J Endovasc Ther 2008;15:363-9.
6. Giles KA, Pomposelli FB, Hamdan AD, Blattman SB, Panossian H,
Schermerhorn ML. Infrapopliteal angioplasty for critical limb ischemia:
relation of TransAtlantic InterSociety Consensus class to outcome in
176 limbs. J Vasc Surg 2008;48:128-36.
7. Siablis D, Karnabatidis D, Katsanos K, Diamantopoulos A, Christeas N,
Kagadis GC. Infrapopliteal application of paclitaxel-eluting stents for
critical limb ischemia: midterm angiographic and clinical results. J Vasc
Interv Radiol 2007;18:1351-61.
8. Siablis D, Karnabatidis D, Katsanos K, Kagadis GC, Kraniotis P, Dia-
mantopoulos A, Tsolakis J. Sirolimus-eluting versus bare stents after
suboptimal infrapopliteal angioplasty for critical limb ischemia: endur-
ing 1-year angiographic and clinical benefit. J Endovasc Ther 2007;14:
241-50.
9. Siablis D, Kraniotis P, Karnabatidis D, Kagadis GC, Katsanos K, Tso-
lakis J. Sirolimus-eluting versus bare stents for bailout after suboptimal
infrapopliteal angioplasty for critical limb ischemia: 6-month angio-
graphic results from a nonrandomized prospective single-center study. J
Endovasc Ther 2005;12:685-95.
10. Rosales OR, Mathewkutty S, Gnaim C. Drug eluting stents for below
the knee lesions in patients with critical limb ischemia: long-term
follow-up. Catheter Cardiovasc Interv 2008;72:112-5.
11. Commeau P, Barragan P, Roquebert PO. Sirolimus for below the knee
lesions: mid-term results of SiroBTK study. Catheter Cardiovasc Interv
2006;68:793-8.
12. Schernthaner R, Stadler A, Lomoschitz F, Weber M, Fleischmann D,
Lammer J, Loewe Ch.Multidetector CT angiography in the assessment
of peripheral arterial occlusive disease: accuracy in detecting the severity,
number, and length of stenoses. Eur Radiol 2008;18:665-71.Submitted Mar 9, 2009; accepted Apr 24, 2009.
